Study wrapper · #836
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
Editor's note
This pharmacovigilance analysis is directly about both tracked peptides. Using FDA adverse-event reports through March 2026, researchers ran disproportionality and Bayesian analyses in women aged 12–55 and found that semaglutide had the broadest signal — disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, clots, oligomenorrhea, and anovulatory cycles — while tirzepatide showed narrower signals (intermenstrual bleeding, clots) and liraglutide showed none. The critical caveat is the data source: FAERS is a spontaneous-reporting system, so it can flag a possible association but cannot establish incidence, causation, or whether the drug or the underlying weight/metabolic change drives the pattern. Reporting is subject to notoriety and stimulated-reporting bias — heavily publicized drugs generate more reports. So this is a signal-generation study, not confirmatory. Its practical value is that it supports raising menstrual health in counseling for reproductive-aged patients on these agents. Weight it as a hypothesis worth prospective study, not as established risk.
Plain-language abstract
Researchers examined whether GLP-1 receptor agonists — including semaglutide and tirzepatide — are linked to menstrual changes in women of reproductive age. They mined the FDA's voluntary side-effect reporting database (reports through March 2026) for women aged 12 to 55 and used statistical methods to see which drugs were reported alongside menstrual problems more often than expected. Semaglutide showed the widest pattern, with more-than-expected reports of heavy periods, bleeding between periods, menstrual clots, infrequent periods, and cycles without ovulation. Tirzepatide showed a narrower pattern (bleeding between periods and clots), and liraglutide showed no clear signal. Important limitation: this database collects side effects that people and doctors choose to report, so it can point to a possible link but cannot prove the drugs cause these changes or say how common they are — and widely publicized drugs tend to attract more reports. The authors suggest doctors discuss menstrual health when prescribing these medications to reproductive-aged patients.